Review of emerging evidence that next-generation obesity drugs may affect male reproductive health, summarizing trials, observational data, and outstanding questions.
Key Takeaways
- Steve Gschmeissner/SPL The latest generation of obesity drugs might have another potential benefit
- Systematic review presented today at the Endocrine Society’s annual meeting in Chicago
- At the end of 16 weeks, the testosterone levels of both groups had risen